Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: A report from the European Group for Blood and Marrow Transplantation

Blood

Volumn 107, Issue 6, 2006, Pages 2578-2584

  Schönland, Stefan O ^a   Lokhorst, Henk ^b   Buzyn, Agnes ^b   Leblond, Veronique ^b   Hegenbart, Ute ^b   Bandini, Giuseppe ^b   Campbell, Andrew ^b   Carreras, Enric ^b   Ferrant, Augustin ^b   Grommisch, Leanthe ^b   Jacobs, Peter ^b   Kröger, Nicolaus ^b   La Nasa, Giorgio ^b   Russell, Nigel ^b   Zachee, Pierre ^b   Goldschmidt, Hartmut ^b   Iacobelli, Simona ^b   Niederwieser, Dietger ^b   Gahrton, Gösta ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; MELPHALAN; PREDNISONE; THALIDOMIDE; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMYLOIDOSIS; ARTICLE; ASCITES; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; BRAIN INFECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONDITIONING; CONTROLLED STUDY; CONVALESCENCE; DISEASE CONTROL; DISEASE SEVERITY; FEVER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GRAFT REJECTION; HEALTH STATUS; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEMODIALYSIS; HUMAN; ISOGRAFT; KAPLAN MEIER METHOD; KIDNEY FAILURE; LIGHT CHAIN; LIVER FAILURE; LYMPHOMA; MORTALITY; NAUSEA; OBSERVATION; ORTHOSTATIC HYPOTENSION; PATIENT SELECTION; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; REGISTER; REMISSION; RETROSPECTIVE STUDY; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; TASK PERFORMANCE;

EID: 33644757671     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2462     Document Type: Article

References (44)

1. Kyle RA, Gertz MA, Greipp PR, et al. Long term survival (10 years or more) in 30 patients with primary amyloidosis. Blood. 1999;93:1062-1066.
2. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202-1207.
3. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85-93.
4. Perz J, Schonland SO, Hundemer M, et al. Highdose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of AL amyloidosis: a single centre prospective phase II study. Br J Haematol. 2004;127: 543-551.
5. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant: a case control study. Blood. 2004;103:3960-3963.
6. Moreau P, Leblond V, Bourquelot P. Prognostic factors of survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101:766-769.
7. Vesole D, Perez WS, Reece DE, et al. High dose therapy with autologous hematopoietic stem cell transplantation (HSCT) for patients with primary systemic amyloidosis (AL): results from the Autologous Blood and Marrow Transplant Registry (ABMTR) [abstract 402]. Blood. 2003;102:118a.
8. Gillmore JD, Apperley JF, Craddock C, et al. High dose melphalan and stem cell rescue for AL amyloidosis. In: Kyle RA, Gertz MA, eds. Amyloid and Amyloidosis. Pearl River, NY: Parthenon Publishing; 1999:102-104.
9. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276-4282.
10. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-1873.
11. Seldin DC, Choufani EB, Dember LM, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma. 2003;3:241-246.
12. Dhodapkar MV, Hussein MA, Rasmussen E, et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood. 2004;104:3520-3526.
13. Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood. 2005;105:2949-2951.
14. Quillen K, Wright DG, Seldin DC, et al. Feasibility of second autologous peripheral blood stem cell (PBSC) collection followed by a second cycle of high dose melphalan (HDM) in patients relapsing after an initial course of HDM for the treatment of AL amyloidosis [abstract 5226]. Blood. 2004;104: 391b.
15. Sanchoralawa V, Wright D, Quillen K, et al. Treatment of AL amyloidosis with tandem cycles of high-dose melphalan and autologous stem cell transplantation [abstract]. Xth International Symposium on Amyloid and Amyloidosis. Tours, April 18-22, 2004, P48.
16. Guillaume B, Straetmans N, Jadoul M, et al. Allogeneic bone marrow transplantation for AL amyloidosis. Bone Marrow Transplant. 1997;20:907-908.
17. Gillmore JD, Davies J, Iqbal A, et al. Allogeneic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol. 1998;100:226-228.
18. Thaunat O, Alyanakian MA, Varnous S, et al. Long-term successful outcome of sequential cardiac and allogeneic bone marrow transplantations in severe AL amyloidosis. Bone Marrow Transplant. 2005;35:419-420.
19. Kawai Y, Kinoshita K, Arai H, et al. Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to highdose melphalan. Eur J Haematol. 2004;72:448-450.
20. Gertz MA, Blood E, Vesole DH, et al. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant. 2004;34: 149-154.
21. Sanchorawala V, Wright DG, Seldin DC, et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant. 2004;33:381-388.
22. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10(th) International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005;79:319-328.
23. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337:898-909.
24. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346:1786-1791.
25. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
26. Sullivan, KM. Graft-versus-host-disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. 2nd ed. Boston, MA: Blackwell Science; 1999: 515-536.
27. Gooley TA, Leisenring W, Crowley Ja, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representation of old estimators. Statistics Med. 1999;18:695-706.
28. Van Buren M, Hene RJ, Verdonck LF, et al. Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis. Ann Intern Med. 1995;122:508-510.
29. Lachmann HJ, Gallimore R, Gillmore JD et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78-84.
30. Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the chronic leukemia working party of the EBMT. Blood. 2005;105:4532-4539.
31. Schetelig J, Thiede C, Bornhauser M, et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol. 2003;21:2747-2753.
32. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet. 1998;352:1087-1092.
33. Kern W, Schleyer E, Braess J, et al. Efficacy of fludarabine, intermittent sequential high dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias. Ann Hematol. 2001;80:334-339.
34. Bellucci R, Ritz J. Allogeneic stem cell transplantation for multiple myeloma. Rev Clin Exp Hematol. 2002;6:205-224.
35. Hegenbart U, Niederwieser D, Forman S, et al. Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Transplant. 2003;9:689-697.
36. Goldschmidt H, Hegenbart U, Wallmeier M, et al. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann Oncol. 1997;8:243-246.
37. Bjorkstrand B. European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. Semin Hematol. 2001;38:219-225.
38. Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99:731-735.
39. Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113:209-216.
40. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. 2004;104:1550-1558.
41. Crawley C, Iacobelli S, Björkstrand B, et al. Reduced-intensity conditioning does not improve survival compared to standard conditioning for patients with myeloma [abstract]. Bone Marrow Transplant. 2005;35(suppl 2):S48.
42. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003;102:756-762.
43. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004;104:961-968.
44. Lokhorst HM, Segeren CM, Verdonck LF, et al. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol. 2003;21:1728-1733.